ECB-ART-50120
J Thorac Oncol
2012 May 01;75:924-33. doi: 10.1097/JTO.0b013e31824cc334.
Show Gene links
Show Anatomy links
Genetic changes in squamous cell lung cancer: a review.
Heist RS
,
Sequist LV
,
Engelman JA
.
???displayArticle.abstract???
Identifying specific somatic mutations that drive tumor growth has transformed the treatment of lung cancer. For example, cancers with sensitizing epidermal growth factor receptor mutations and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase translocations can have remarkable responses to epidermal growth factor receptor and ALK inhibitors respectively, leading to significant clinical benefit. However, effective molecularly targeted therapies have disproportionately impacted adenocarcinomas compared to squamous cell carcinomas, and never or light smokers compared to heavy smokers. Further progress in non-small-cell lung cancer will require the identification and effective targeting of molecular alterations in all subtypes of lung cancer. Here, we review the current knowledge about the molecular alterations found in squamous cell carcinoma of the lung. First, we will discuss the ongoing efforts to comprehensively assess the squamous cell carcinoma genome. We will then discuss the evidence supporting the role of specific genes in driving squamous cell carcinomas. By describing the landscape of somatic targets in squamous cell lung cancer, we hope to crystallize the current understanding of potential targets, spur development of therapies that can have clinical impact, and underscore the importance of new discoveries in this field.
???displayArticle.pubmedLink??? 22722794
???displayArticle.pmcLink??? PMC3404741
???displayArticle.link??? J Thorac Oncol
???displayArticle.grants??? [+]
References [+] :
Acevedo,
Paths of FGFR-driven tumorigenesis.
2009, Pubmed
Acevedo, Paths of FGFR-driven tumorigenesis. 2009, Pubmed
Balsara, Chromosomal imbalances in human lung cancer. 2002, Pubmed
Bass, SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. 2009, Pubmed
Beroukhim, The landscape of somatic copy-number alteration across human cancers. 2010, Pubmed
Birchmeier, Met, metastasis, motility and more. 2003, Pubmed
Björkqvist, DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. 1998, Pubmed
Brannan, Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. 2009, Pubmed
Brass, Amplification of the genes BCHE and SLC2A2 in 40% of squamous cell carcinoma of the lung. 1997, Pubmed
Cappuzzo, Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. 2010, Pubmed
Carpten, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 2007, Pubmed
Carretero, Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. 2004, Pubmed
Carretero, Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. 2010, Pubmed
Ciuleanu, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. 2009, Pubmed
Comtesse, Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. 2007, Pubmed
Courtney, The PI3K pathway as drug target in human cancer. 2010, Pubmed
Dacic, Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. 2006, Pubmed
Davies, Somatic mutations of the protein kinase gene family in human lung cancer. 2005, Pubmed
Denissenko, Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. 1996, Pubmed
Ding, Somatic mutations affect key pathways in lung adenocarcinoma. 2008, Pubmed
Dziadziuszko, The insulin-like growth factor pathway in lung cancer. 2008, Pubmed
Dziadziuszko, Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. 2010, Pubmed
Ekstrand, Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. 1992, Pubmed
Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations. 2009, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Fang, A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. 2005, Pubmed
Faoro, EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. 2010, Pubmed
Ford, Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. 2007, Pubmed
Garnis, High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. 2006, Pubmed
Go, High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. 2010, Pubmed
Greenman, Patterns of somatic mutation in human cancer genomes. 2007, Pubmed
Gualberto, Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. 2010, Pubmed
Gualberto, Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. 2011, Pubmed
Haber, Cancer: drivers and passengers. 2007, Pubmed
Hainaut, Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. 2001, Pubmed
Hainsworth, BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. 2011, Pubmed
Hammerman, Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. 2011, Pubmed
Hanna, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. 2004, Pubmed
Haugsten, Roles of fibroblast growth factor receptors in carcinogenesis. 2010, Pubmed
Hecht, Tobacco smoke carcinogens and lung cancer. 1999, Pubmed
Higashiyama, MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. 1997, Pubmed
Hirsch, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. 2003, Pubmed
Hoffmann, The changing cigarette, 1950-1995. 1997, Pubmed
Hollander, PTEN loss in the continuum of common cancers, rare syndromes and mouse models. 2011, Pubmed
Hussenet, SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. 2010, Pubmed
Hussenet, SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. 2010, Pubmed
Ikeda, Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. 2002, Pubmed
Ji, Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. 2006, Pubmed
Ji, LKB1 modulates lung cancer differentiation and metastasis. 2007, Pubmed
Jin, PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. 2010, Pubmed
Kan, Diverse somatic mutation patterns and pathway alterations in human cancers. 2010, Pubmed
Kang, Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. 2009, Pubmed
Karp, Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. 2009, Pubmed
Kawano, PIK3CA gene amplification in Japanese non-small cell lung cancer. 2007, Pubmed
Kawano, PIK3CA mutation status in Japanese lung cancer patients. 2006, Pubmed
Kettunen, A broad amplification pattern at 3q in squamous cell lung cancer--a fluorescence in situ hybridization study. 2000, Pubmed
Kim, Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. 2010, Pubmed
Kinch, Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 2003, Pubmed
Kishimoto, Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. 1992, Pubmed
Koivunen, Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. 2008, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Larsen, Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. 2007, Pubmed
Lee, Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. 2010, Pubmed
Lockwood, Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. 2010, Pubmed
Lu, Evidence that SOX2 overexpression is oncogenic in the lung. 2010, Pubmed
Luk, Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. 2001, Pubmed
Lynch, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004, Pubmed
López-Malpartida, Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. 2009, Pubmed
Malanga, Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. 2008, Pubmed
Mandinova, The p53 pathway as a target in cancer therapeutics: obstacles and promise. 2011, Pubmed
Marsit, PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. 2005, Pubmed
Mason, Initiation to end point: the multiple roles of fibroblast growth factors in neural development. 2007, Pubmed
Massion, Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. 2002, Pubmed
Matsumoto, Prevalence and specificity of LKB1 genetic alterations in lung cancers. 2007, Pubmed
Meyerson, Advances in understanding cancer genomes through second-generation sequencing. 2010, Pubmed
Mok, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 2009, Pubmed
Momand, The MDM2 gene amplification database. 1998, Pubmed
Nasreen, Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. 2006, Pubmed
Okudela, PIK3CA mutation and amplification in human lung cancer. 2007, Pubmed
Olaso, Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. 2002, Pubmed
Onozato, LKB1 gene mutations in Japanese lung cancer patients. 2007, Pubmed
Ou, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. 2011, Pubmed
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Pao, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004, Pubmed
Pasquale, Eph receptor signalling casts a wide net on cell behaviour. 2005, Pubmed
Pei, Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. 2001, Pubmed
Petersen, Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. 1997, Pubmed
Pirker, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. 2012, Pubmed
Pleasance, A small-cell lung cancer genome with complex signatures of tobacco exposure. 2010, Pubmed
Ramos, Amplification of chromosomal segment 4q12 in non-small cell lung cancer. 2009, Pubmed
Rikova, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007, Pubmed
Robles, The p53 network in lung carcinogenesis. 2002, Pubmed
Saito, Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. 2004, Pubmed
Samuels, High frequency of mutations of the PIK3CA gene in human cancers. 2004, Pubmed
Sandler, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 2006, Pubmed
Sarkaria, Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. 2006, Pubmed
Sasaki, EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. 2007, Pubmed
Scagliotti, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. 2008, Pubmed
Scagliotti, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. 2009, Pubmed
Schiller, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. 2002, Pubmed
Shackelford, The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. 2009, Pubmed
Shibata, Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. 2008, Pubmed
Shields, Molecular epidemiology of smoking and lung cancer. 2002, Pubmed
Singh, Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. 2006, Pubmed
Smith, Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. 2000, Pubmed
Smolen, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. 2006, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Soder, Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. 1997, Pubmed
Solis, Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. 2010, Pubmed
Thomas, High-throughput oncogene mutation profiling in human cancer. 2007, Pubmed
Tonon, High-resolution genomic profiles of human lung cancer. 2005, Pubmed
Weir, Characterizing the cancer genome in lung adenocarcinoma. 2007, Pubmed
Weiss, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010, Pubmed
Wong, Structural alterations of the epidermal growth factor receptor gene in human gliomas. 1992, Pubmed
Wu, Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. 2008, Pubmed
Yamamoto, PIK3CA mutations and copy number gains in human lung cancers. 2008, Pubmed
Zhao, Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. 2005, Pubmed